Protective effects of Colomast®, A New Formulation of Adelmidrol and Sodium Hyaluronate, in A Mouse Model of Acute Restraint Stress
Laboratory studyOther animalsWith adelmidrol (a PEA analogue) with sodium hyaluronate (Colomast)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue) with sodium hyaluronate (Colomast). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice subjected to acute restraint stress (numbers not stated in the abstract)
- Dose used in the study
- Colomast 20 mg/kg by oral gavage 30 minutes before immobilisation
- Duration
- Single pre-treatment; stress lasted 2 hours
- What was measured
- Gut histology, cytokines, neutrophil infiltration, mast cell activation, oxidative stress, NF-kappa-B and apoptosis pathways; tight junction proteins in ileum, hippocampus and cortex; depression- and anxiety-like behaviours
What the authors reported
This laboratory study found:
- Colomast pre-treatment reduced gut histological damage, cytokine expression, neutrophil infiltration, mast cell activation and oxidative stress, and modulated NF-kappa-B and apoptosis pathways after restraint stress.
- It restored tight junctions in ileum, hippocampus and cortex.
- It reduced depression- and anxiety-related behaviours.
- No numbers are given in the abstract.
Limits of this study
A mouse model of acute stress; it cannot show effect in people or animals treated in practice. The product tested is adelmidrol plus hyaluronate, not palmitoylethanolamide itself. Salvatore Cuzzocrea holds patents with Epitech Group, which the authors say are unrelated to the study.
Source
PubMed 33143356 · doi:10.3390/ijms21218136
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.